We are thrilled to announce that Biocytogen will exhibit at the 17th World ADC San Diego from October 12th - 15th. Tune in to a special talk hosted by our Chief Scientific Officer, Benny Yang, on RenSuper™ Biologics: Empowering Next-Gen Dual-Payload ADCs with AI-Driven Precision and Scalability. Come meet our experts at booth #104 to learn more about our AI-powered fully human antibody discovery platforms and target-humanized mouse models supporting the discovery, optimization, and preclinical evaluation of ADCs.
What is 17th World ADC San Diego?
17th World ADC San Diego is a premier conference that brings together the global ADC community for an unparalleled amalgamation of case studies, development trends and impactful networking opportunities to force ADC innovation into differentiated, early-line patient outcomes.
Event Overview
Date: October 12th - 15th, 2026
Venue: Town & Country Resort, 500 Hotel Circle North, San Diego, CA, 92108
Booth: 104
Speaker Session
Title: RenSuper™ Biologics: Empowering Next-Gen Dual-Payload ADCs with AI-Driven Precision and Scalability
Speaker: Benny Yang
Date: October 13th
Time: 12:30 PM
Posters
BCG048, a Novel Bispecific Dual-payload ADC Targeting ITGB6/B7H3 Showed Strong Preclinical Efficacy
BCG026: a Novel FAP x GPC1 Bispecific ADC Targeting Stromal and Tumor Cells in Pancreatic Cancer and Other Solid Tumors
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
